Evidence map›Paper›PMID 30960988›Full record

ArticlePolymers2018

Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor.

Santhosh Kalash Rajendrakumar, Adityanarayan Mohapatra, Bijay Singh, Vishnu Revuri, Yong-Kyu Lee, Chang Seong Kim, Chong-Su Cho, In-Kyu Park

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Polymers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Bioactive Nanoparticles for Cancer Immunotherapy.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Santhosh Kalash RajendrakumarDepartment of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 501-746, Korea. kalash1288@gmail.com.
Adityanarayan MohapatraDepartment of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 501-746, Korea. mkaditya55@gmail.com.
Bijay SinghResearch Institute for Bioscience and Biotechnology, Nakkhu-4, Lalitpur 44600, Nepal. singhbijay@ribb.org.np.
Vishnu RevuriDepartment of Green Bioengineering, Korea National University of Transportation, Chungju 27469, Korea. vishnurevuri91@gmail.com.
Yong-Kyu LeeDepartment of Green Bioengineering, Korea National University of Transportation, Chungju 27469, Korea. yklee09@naver.com.
Chang Seong KimDepartment of Internal Medicine, Chonnam National University Medical School, 42 Jebongro, Gwangju 501-757, Korea. laminion@hanmail.net.
Chong-Su ChoDepartment of Agricultural Biotechnology and Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 08826, Korea. chocs@snu.ac.kr.
In-Kyu ParkDepartment of Biomedical Science and BK21 PLUS Center for Creative Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju 501-746, Korea. pik96@jnu.ac.kr.ORCID 0000-0002-8522-8236
Chonnam National University · KRKorea National University of Transportation · KRResearch Institute for Bioscience and Biotechnology · NPSeoul National University · KR

Funding

Basic Science Research Program 2016R1A2B4011184 & 2016K2A9A1A06921661Chonnam National University Hwasun Hospital Institute for Biomedical Science HCRI 17901-22the Bio & Medical Technology Development Program, National Research Foundation of Korea (NRF) , MSIP NRF-2017M3A9F5030940 & NRF-2017M3A9E2056374the Pioneer Research Center Program through the National Research Foundation of Korea, Ministry of Science, ICT & Future Planning 2014M3C1A3053035
6 · The paper itself

Abstract

Malignant melanoma is a highly aggressive type of cancer that requires radical treatment strategies to inhibit the cancer cell progression and metastasis. In recent years, preclinical research and clinical trials on melanoma treatment have been considerably focused on the adjuvant-based immunotherapy for enhancing the immune response of innate immune cells against cancer cells. However, the clinical outcome of these adjuvant-based treatments is inadequate due to an improper delivery system for these immune activators to reach the target site. Hence, we developed a vaccine formulation containing tumor lysate protein (TL) and poly I:C (PIC) complexed with positively charged poly (sorbitol-

Indexed as

adjuvantantigenimmunotherapymelanomapolyethyleniminepoly I:C

Identifiers

PMID30960988
PMCPMC6404041
OpenAlexW2891058291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.